Stockwinners Market Radar for February 07, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:11 EST Cathie Wood's ARK Investment bought 148.8K shares of Velo3D today

19:35 EST CSX reaches agreement with union workers on paid sick leave - The company states: "CSX announced that it has reached agreements with two unions that provide paid sick leave for approximately 5,000 railroad workers. The agreements were reached with the Brotherhood of Maintenance of Way, which represent engineering employees, and the Brotherhood of Railway Carmen, representing mechanical workers."

18:53 EST Cactus announces expiration of HSD waiting period for pending FlexSteel deal - Cactus announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to the previously announced agreement to acquire FlexSteel Technologies Holdings, Inc. and its affiliates through a merger with its holding company, HighRidge Resources, Inc. and Atlas Merger Sub, LLC, a newly formed subsidiary of Cactus, Inc. The expiration of the HSR waiting period occurred at 11:59 p.m. Eastern Standard Time on February 6, 2023, without any action taken by the Federal Trade Commission or the U.S. Department of Justice. This was a condition to the closing of the pending transaction. Completion of the transaction is subject to the satisfaction of the remaining customary closing conditions and is expected to occur during the first quarter of 2023.

18:20 EST Charles Schwab chairman sells $25.4M of common stock - In a regulatory filing, Charles Schwab disclosed that its chairman Charles Schwab sold 318K shares of common stock on February 3rd in a total transaction size of $25.4M.

18:01 EST Gorilla secures first U.K. customer - The company states: "Gorilla Technology Group announced that it secured its first U.K. customer for its edge-based Video Analytics solution for a port owner upgrading its infrastructure to enable more efficient operations through intelligent "Smart Port" functionality." Gorilla Chief Innovation Officer Dr. Rajesh Natarajan said: "This deal brings our edge-based Video Analytics solution to the transportation industry in Europe, helping to enable the growing trend of 'Smart Ports'. Our Edge AI product will help determine if vehicles and their cargo are identified based on their serial numbers, are properly certified, and are undamaged. This solution can be applied to both air and sea ports, creating a large new growth opportunity for us in the U.K. port industry, which transported more than 445 million tons of cargo in 2021, according to UK Department for Transport."

17:53 EST User reports indicate problems at Sony's PlayStation Network, Downdetector says - Reference Link

17:36 EST Mercer joint venture announces planned curtailment of operation - Mercer announced that the operator of the Cariboo Pulp and Paper mill, in which Mercer has a joint venture interest, has announced a planned curtailment of operation beginning in mid-April for a month and then for another month in the third quarter. The announcement is the direct consequence of a decrease in availability of fiber, which is well documented in British Columbia. Recent insect infestation, fire, and Government policy have all impacted the amount of available fiber in the region. Downtime at the mill will better align production capacity with the available fiber supply. These plans may be adjusted should fiber forecasts change.

17:17 EST eBay announces 4% workforce reduction - On February 7, Jamie Iannone, CEO of eBay, shared the following message with eBay employees: "Team, Over the past few months, we've taken a thoughtful look at where we are as a company with considerations of the macroeconomic situation around the world and how to best invest and operate so that we can continue to be successful. To create long-term, sustainable growth for eBay, we need to evolve our organization as we take the next step in our strategy - focused on driving growth, building a trusted marketplace, empowering enthusiasts and seeding new technologies for the future. As a result of these considerations and our future-forward plans, I have some hard news to share. Over the next 24 hours, we'll be letting approximately 500 employees globally know that their jobs will be eliminated. This number represents about 4% of our total employee base. In some locations, the notifications are proposals subject to consultation as required by applicable law. There is no easy way to communicate this - but I do want to share with you why we are making this decision, and where we're headed next. Today's actions are designed to strengthen our ability to deliver better end-to-end experiences for our customers and to support more innovation and scale across our platform. They also help us make sure we're concentrating on where we can make the biggest impact, including expanding Focus Categories, creating trusted experiences and investing in new technologies. Importantly, this shift gives us additional space to invest and create new roles in high-potential areas - new technologies, customer innovations and key markets - and to continue to adapt and flex with the changing macro, ecommerce and technology landscape. We're also simplifying our structure to make decisions more effectively and with more speed. On a more personal note, I want to acknowledge that while these actions will move our business forward, they also affect our colleagues. For those directly impacted by these changes, I know this news is particularly difficult. Thank you for your incredible talent, passion, and achievements to help get us to where we are today. I'm so grateful for the impact that you made at eBay. We want to support you as you navigate the transition including providing comprehensive transition packages with severance and employee incentive payments. While today's actions are not easy, I know this team will come together to support each other as eBayers always do. The dedication and commitment that you all bring every day on behalf of our customers - and each other - inspires me every day. I look forward to the opportunities for growth and innovation in our future."

17:07 EST VF Corp. expects Vans to be down high single digit percentage range in FY23 - Says Vans needs to perform better. Says VF portfolio in America must grow more consistently. Says in a difficult environment. Says higher lead time has impacted the business, but lead times are improving as anticipated. Sees North Face up at least 14% in FY23. Sees FY23 gross margin down 200 basis points Sees FY23 operating margin 9%. Sees FY23 tax rate 13%. Sees FY23 capital expenditures $200M. Comments and guidance taken from Q3 earnings conference call.

17:03 EST Gentex announces settlement with SEC - As previously disclosed, Gentex has been responding to an investigation by the staff of the Division of Enforcement of the SEC regarding certain accounting determinations that could have impacted the company's reported earnings per share for certain prior quarterly periods. On February 7, 2023, the SEC announced that it has accepted an Offer of Settlement submitted by the company and its current CFO Kevin Nash. Under the settlement, without admitting or denying the SEC's findings in this matter, the company and Nash have consented to the entry of an administrative civil cease-and-desist order by the SEC with respect to certain violations of the federal securities laws in the third quarter of 2015 through the second quarter of 2018. The company has agreed to pay a civil monetary penalty of $4M, which was fully accrued by the company in the second and third quarters of 2022. Nash has agreed to pay a civil monetary penalty of $75,000. The Order states that, during the Relevant Period, the company had deficiencies in its accounting for its employee bonus compensation programs, and failed to maintain accurate books and records and sufficient internal accounting controls, in violation of Sections 13(a), 13(b)(2)(A) and 13(b)(2)(B) of the Securities Exchange Act of 1934 and Rules 13a-11, 13a-13, 13a-15, and 12b-20 thereunder. The Order further states that, during the Relevant Period and while serving as Chief Accounting Officer, Nash did not sufficiently document the bases for certain accounting entries, in violation of Section 13(b)(5) of the Exchange Act and Rule 13b2-1 thereunder, and causing the company's violations of Exchange Act Sections 13(a), 13(b)(2)(A), and 13(b)(2)(B), and Rules 13a-11, 13a-13, 13a-15, and 12b-20 thereunder.

17:01 EST Bunge increases monitoring of soybeans from indirect supply chain in Brazil - Bunge announced it has achieved 80% traceability and monitoring of soybeans from its indirect supply chain in the Brazilian Cerrado. Launched in 2021, Bunge's Sustainable Partnership Program was designed to help grain resellers assess suppliers' social-environmental performance. Through the program, Bunge shares its experience, methodologies and tools with grain resellers to enable them to bring to market commodities of proven sustainable origin. The program offers access to verification systems, such as satellite and farm-scale images to advance the traceability and monitoring of farms. "The program reaffirms Bunge's active role in engaging and positively influencing the entire supply chain in Brazil and remains an important instrument in helping the company achieve its goal of deforestation-free chains in 2025," says Pamela Moreira, Bunge's Sustainability Senior Manager for South America. "Since 2018, Bunge has been able to fully trace back to third-party elevators, so the next step was to expand our focus to soybeans acquired through our indirect supply chain in the Brazilian Cerrado. The strategy has led to positive results and strong adoption among grain resellers." To further strengthen the program, Bunge is enhancing its partnership with Vega Monitoramento, an agtech company which uses LYRA platform for remote sensing, artificial intelligence, and structured data to perform the socio-environmental diagnosis of agricultural properties.

16:53 EST Enphase Energy CEO says January activations are holding up - CEO Kothandaraman says: "Even with the pronounced seasonality and sell-through in January, we'd like to point out that our activations are holding up. The second point to also note is that in conversations with our installers and distributor partners, they have started to see originations pick up in January when compared to December. Although the data we have is limited, these two points make us cautiously optimistic about Q2." Comments taken from Q4 earnings conference call.

16:39 EST nCino expands nCino IQ offerings through partnership with rich data company - nCino announced a value added reseller agreement with Rich Data Co an industry leading artificial intelligence decisioning platform, to enhance the lending process for its customers. The combined value delivered by this partnership will equip financial institutions with deeper insights into their clients' business and improve, streamline and further automate workflow and monitoring, creating significant value and efficiencies in small business and commercial lending.nCino will integrate RDC's decisioning capabilities into the nCino Bank Operating System to enhance nCino's Commercial Banking and Small Business Banking solutions with ground-breaking AI and machine learning techniques. This will simplify the traditional credit technology landscape and empower transparent and explainable decision-making driving revenue and efficiency for nCino's customers. The partnership with RDC will expand the use cases for nCino IQ , which leverages intelligence and machine learning to transform data into information and actionable insights, empowering financial institutions to focus on key-value add activities and make better business decisions.

16:37 EST Asur reports January passenger traffic up 29.8% from last year - Grupo Aeroportuario del Sureste announced that passenger traffic for January reached a total of 6.3M passengers, 29.8% above the levels reported in January 2022. Compared to January 2022, passenger traffic increased by 37.8% in Puerto Rico, 33.6% in Mexico and 16.6% in Colombia. Passenger traffic growth all regions of operations was driven by increases in both domestic and international traffic. In Puerto Rico, Mexico and Colombia domestic traffic increased 36.8%, 35.0% and 10.5%, respectively, while international traffic increased 49.6%, 32.4% and 50.8%, respectively.

16:30 EST ePlus says it is well positioned to capitalize key growth trends - "Our solid financial results in the Q3 and through the first nine months of FY23 speak to the fundamental strength of our business, our expanded portfolio of solutions and services and the dedication of our team. Supported by the strength of our balance sheet and our extensive partnerships within the global IT market, ePlus remains well positioned to capitalize on key long-term growth trends, such as workplace transformation, the need to protect against cybersecurity threats and the shift to the cloud," said Mark Marron, president and chief executive officer of ePlus.

16:27 EST Midland States boosts dividend 3.4% to 30c per share - Midland States Bancorp announced that its Board of Directors declared a quarterly cash dividend of 30c per share of its common stock, an increase of 3.4% from the previous quarterly cash dividend of 29c per share. The dividend is payable on February 24 to all shareholders of record as of the close of business on February 17. The Board of Directors also declared a cash dividend of $0.4844 per depository share on its 7.750% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A. The dividend will be payable on March 30 to stockholders of record as of March 15.

16:26 EST Arconic reports $304M after-tax loss on sale of Russian operations - As previously announced, Arconic Corporation completed the sale of 100% of its Russian operations on November 15, 2022. As a result of the divestiture, and consistent with the sale announcement, the company recorded a $304M after-tax loss on the sale in the fourth quarter of 2022. In addition, the company's previous 2022 Adjusted EBITDA outlook, which included a full year of operating activity for the divested business, will be reduced by an estimated $9M.

16:25 EST Midland States boosts dividend 3.4% to 30c per share - Midland States Bancorp announced that its Board of Directors declared a quarterly cash dividend of 30c per share of its common stock, an increase of 3.4% from the previous quarterly cash dividend of 29c per share. The dividend is payable on February 24, 2023 to all shareholders of record as of the close of business on February 17, 2023.Jeffrey G. Ludwig, President and Chief Executive Officer of the Company, said, "This dividend declaration represents the 23rd consecutive year that Midland States Bancorp has increased its quarterly cash dividend. We are pleased that our financial performance enables us to increase the amount of capital that we return to shareholders through our quarterly dividend while also retaining a sufficient amount of capital to increase our capital ratios to better support the continued growth of our franchise."

16:24 EST ViaSat anticipates achieving positive free cash flow in spring of calendar 2025 - Approximately two quarters later than prior guidance.

16:20 EST Anthony Hsieh nominates Steven Ozonian for election to board of LoanDepot - Anthony Hsieh, the Founder of LoanDepot, who holds over 40% of the economic interest and approximately 57% of the combined voting power of the company, announced in a letter to loanDepot stockholders that he has nominated Steven Ozonian for election to the company's Board at the company's 2023 Annual Meeting of Stockholders. Hsieh intends to vote all of his shares in favor of Ozonian. Hsieh has engaged with the Board over the last few months in an effort to persuade members of the urgent need for board refreshment to address the challenges the company faces in this economic environment. Because the Board has not been receptive to these efforts, Hsieh has exercised his right as a stockholder to unilaterally nominate Ozonian for election at the next Annual Meeting of Stockholders in place of one of the company's existing incumbent directors. Hsieh explained his reasoning to fellow stockholders writing, "As leaders of this company and stewards of stockholder capital, the Board must always challenge itself to be a dynamic center of passionate, informed and relevant perspectives to help guide the company to future success. Mr. Ozonian's experience and perspective will be additive to the loanDepot Board of Directors at this critical juncture for the company. The recent rise in rates and challenging macroeconomic environment make Mr. Ozonian's potential appointment all the more urgent."

16:20 EST VF Corp. sees $225M of annualized savings in fiscal 2024 - The company said its strategic actions include: "Concluding a number of asset sales during H2'FY23, including the sale and leaseback of VF's European headquarters in Stabio, Switzerland; Reducing working capital and aligning inventories to optimal levels, without compromising brand equity; Increasing our efforts to reduce costs in order to point resources toward the Company's highest value creation opportunities, including completing the previously announced actions which will deliver approximately $225 million in annualized savings once complete in FY24."

16:17 EST VF Corp. cuts quarterly dividend to 30c from 51c per share - VF Corp. said its capital deployment priorities in the near to medium term are focused on optimizing and driving the performance of the portfolio, reducing leverage and returning capital to shareholders. VF is "also evaluating and deploying a series of strategic actions to strengthen the Company's financial position and sharpen focus on its greatest value creation opportunities," including rightsizing the dividend payout to accelerate the return to the company's target leverage ratio and provide additional financial flexibility, positioning VF to navigate the current macro-economic challenges while continuing to make investments to advance its strategy. As a result, VF's next quarterly per share payment will reduce to 30c from 51c per share. The company expects to grow future dividends in line with earnings.

16:11 EST Chipotle reports Q4 operating margin 13.6%, up from 8.1% last year - Restaurant level operating margin was 24.0%, an increase of 380 basis points. Opened 100 new restaurants with 90 locations including a Chipotlane.

16:08 EST Bed Bath & Beyond: Default under credit agreement waived

16:07 EST Werner sees FY23 CapEx $350M-$400M

16:06 EST Bed Bath & Beyond completes public equity offering, provides strategic update

16:04 EST Vertex Pharmaceuticals board authorizes $3.0B buyback - On February 1, Vertex's Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock.

16:01 EST Acushnet Holdings acquires Club Glove brand, terms not disclosed - Acushnet Holdings announced it has purchased the Club Glove brand from West Coast Trends, Inc. "A highly respected performance leader in travel products, Club Glove is a seamless addition to our portfolio of world-class golf products," said David Maher, Acushnet's President and Chief Executive Officer. "Jeff and Vivienne Herold are to be commended for their 30-plus year commitment to making products of the highest quality and always aspiring to deliver exceptional service experiences. Their focus has built Club Glove into one of the most trusted, category leading brands in golf. At Acushnet, we share this commitment to product and service excellence and look forward to further developing Club Glove as we position the brand for continued success and growth." Acushnet has acquired all relevant Club Glove trademarks, domains and products. West Coast Trends will continue to operate and service the Club Glove brand out of its headquarters in Huntington Beach, California.

15:08 EST Focus Universal announces special stock dividend - Focus Universal is pleased to announce that its Board of Directors declared a special dividend of one share dividend for every two shares of common stock issued and outstanding resulting in a 50% stock dividend of the company's outstanding common stock. There were 43,130,915 shares of the company's common stock outstanding as of February 7. Once the stock dividend is issued, there will be 64,696,373 shares of the company's common stock outstanding. The company's Board set the record date for the dividend as February 23, and the payment date as March 23.

13:56 EST Caterpillar director Dickinson sells 6,070 common shares - In a regulatory filing, Caterpillar director Daniel Dickinson disclosed the sale of 6,070 common shares of the company on February 6 at a price of $251.22 per share.

13:34 EST Delta announces 5% pay raise for employees 'across the board' - Eligible Delta employees have earned a 5% pay increase effective April 1, as the company "continues to invest in the people who lead the industry in operational and customer care excellence," the company stated in a post to its corporate news hub. Delta CEO Ed Bastian announced the pay increase in a memo to employees Tuesday. This latest pay increase provides employees with a total 9% pay increase within the last year, or 4% in May 2022 and 5% in April 2023, Delta noted. "This well-earned increase is a direct result of your efforts," said Delta CEO Ed Bastian. "Delta people are the best in the business, and thanks to your efforts, we're well-positioned to take back the skies, and soar into the future together." Reference Link

13:01 EST Hertz says Teslas made up 11% of vehicle fleet at end of 2022 - Hertz (HTZ) disclosed that during the year ended December 31, 2022, it operated a peak rental fleet in the Americas of 428,700 vehicles. Of that total, Tesla (TSLA) made up 11% of the vehicles, according to Hertz. The rental car company had under 50,000 Tesla at the end of 2022, less than half the 100,000 vehicles Hertz said it would order by the end of the year, Bloomberg points out. Hertz added that it is assembling a "diverse fleet" of electric vehicles "through large-scale acquisition agreements" with Tesla, Polestar and General Motors (GM), starting with an initial order of Teslas made in 2021. "We have established a goal for 25% of our fleet to be electric by the end of 2024. In collaboration with bp pulse, we are also investing in EV infrastructure across our global operations by installing charging stations throughout our network to power our fleet and support customer adoption of EVs," the company said in its annual filing.

12:55 EST Alvarium Tiedemann Holdings Inc trading halted, volatility trading pause

12:34 EST Zoom Video CEO, executive leadership cutting salaries amid layoffs - Zoom Video Communications CEO Eric Yuan said in a blog post, "As the CEO and founder of Zoom, I am accountable for these mistakes and the actions we take today- and I want to show accountability not just in words but in my own actions. To that end, I am reducing my salary for the coming fiscal year by 98% and foregoing my FY23 corporate bonus. Members of my executive leadership team will reduce their base salaries by 20% for the coming fiscal year while also forfeiting their FY23 corporate bonuses...We are humbled to be realizing Zoom's platform vision, but we still have a lot of hard work ahead of us to ensure we're delivering an experience that enables a new kind of productivity - one that brings all the best tools and applications for modern, engaging collaboration into one destination. While we have to take these steps today, we will continue to invest in key strategic areas to help us reach our vision."

12:29 EST Zoom Video announces 15% workforce reduction

12:00 EST GameStop falls -11.7% - GameStop is down -11.7%, or -$2.79 to $21.07.

12:00 EST BrightView falls -22.1% - BrightView is down -22.1%, or -$1.84 to $6.50.

12:00 EST Getty Images rises 10.1% - Getty Images is up 10.1%, or 70c to $7.63.

11:34 EST Digital Ally announces 1-for-20 reverse stock split - Digital Ally announced a 1-for-20 reverse split of the Company's common stock. On February 6, 2023, the Company filed a certificate of amendment to the Company's articles of incorporation, as amended, with the Secretary of State of the State of Nevada to effect the Reverse Stock Split. The Company anticipates that the Common Stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis at the start of trading on February 8, 2023 and will have a new CUSIP number of 25382T200.

11:13 EST Criteo up 13% after Reuters says company exploring possible sale

11:08 EST Criteo trading halted, volatility trading pause

10:54 EST Mountain Crest Acquisition Corp III trading halted, volatility trading pause

10:46 EST Boeing sued by Comair for fraud over the 737 Max aircraft - Comair Limited filed a lawsuit in federal court against The Boeing Company for fraud and breach of contract concerning the purchase of eight 737 MAX aircraft. Comair is seeking damages in excess of $83M, which it suffered as a result of Boeing's wrongful conduct, it said in a statement.

10:37 EST Kontrol Technologies receives notice of allowance for U.S. patent on BioCloud - Kontrol Technologies received a Notice of Allowance for its U.S. Patent Application No. 17/105,804. The Notice of Allowance allows for claims relating to an Air Sampling System having, among other features, an air intake unit defining an inlet and an air inflow channel; a fan configured to cause air in a sampling environment to flow into the air inflow channel via the inlet; a cooling unit for cooling air in the air inflow channel; a collection chamber for collecting liquid water condensed from air in the air inflow channel, the collection chamber being removably coupled to the air intake unit and including an active target substrate having a surface that is coated with bioreceptors; a flow column that is centrally disposed inside the collection chamber, the flow column being fluidly connected to the air inflow channel and defining a plurality of apertures through which fluid flows into the collection chamber; and an optical detection unit including a light source, the optical detection unit being configured to illuminate the active target substrate with the light source, wherein the collection chamber includes: a plurality of glass beads disposed in an annular space between the flow column and an inner wall of the collection chamber, wherein surfaces of the plurality of glass beads are exposed to liquid that collects in the collection chamber; and a permeable stopper that supports the plurality of glass beads above and in spaced relation to a bottom wall of the collection chamber, wherein the active target substrate is disposed in a reaction compartment defined by the stopper and the bottom wall of the collection chamber. Following the receipt of the Notice of Allowance the Company anticipates a Patent to be issued in Q1, 2023.

10:29 EST GD Culture Group Ltd trading resumes

10:18 EST Oak Street Health notes policy not to comment on unusual market activity - Oak Street Health announced that in view of the unusual market activity in the Company's stock, the New York Stock Exchange has contacted the Company in accordance with the Exchange's usual practice. The Company stated that its policy is not to comment on unusual market activity.

10:10 EST AERWINS Technologies Inc trading resumes

10:02 EST Eaton awarded contract to support AEP Ohio microgrid development - Eaton announced it was awarded a contract to help AEP Ohio enhance the resilience and sustainability of critical water infrastructure in Columbus at the Tussing Water Booster Station. The project will establish the city's first renewable energy microgrid and extend Columbus' ability to deliver safe and clean water during extended electric grid outages. The microgrid project is fully commissioned and expected to be energized in Q1 2023.

10:01 EST GE Digital signs collaboration agreement with AWS - GE Digital (GE), an energy software leader, announced that it has signed a multiyear strategic collaboration agreement with Amazon Web Services (AMZN) aimed at helping utilities accelerate grid modernization. Through this collaboration, GE Digital and AWS plan to deliver intelligent grid orchestration solutions. These software solutions will help utilities digitally transform, modernize the power grid, and accelerate the energy transition, the companies said. "Achieving the goal of a clean energy grid requires utilities and their technology partners to accelerate and scale the deployment of innovative, secure, and cost-effective solutions," said Mahesh Sudhakaran, General Manager of Grid Software at GE Digital.

10:00 EST Chegg falls -20.4% - Chegg is down -20.4%, or -$4.29 to $16.74.

10:00 EST TAL Education rises 10.1% - TAL Education is up 10.1%, or 62c to $6.79.

10:00 EST Oak Street Health rises 31.3% - Oak Street Health is up 31.3%, or $8.13 to $34.09.

09:47 EST Turkcell falls -9.4% - Turkcell is down -9.4%, or -46c to $4.45.

09:47 EST TAL Education rises 8.3% - TAL Education is up 8.3%, or 52c to $6.69.

09:47 EST Oak Street Health rises 31.3% - Oak Street Health is up 31.3%, or $8.12 to $34.08.

09:35 EST Bed Bath & Beyond trading halted, volatility trading pause

09:24 EST Helbiz announces plan to issue digital dividend coupons to 'reward investors' - Helbiz announced its plans to issue digital dividend coupons to its shareholders. The idea to issue a special type of dividend-in-property was proposed by the company's founder and CEO, Salvatore Palella, as an innovative way to reward its genuine investors for their continued support."Our commitment to driving innovation and shaping the future is on full display with this historic move, and we look forward to working closely with regulators in our efforts to innovate in the capital markets."...Helbiz is collaborating with a specialized advisory firm to establish the correct digital dividend coupon structure and guarantee a secure, transparent, and robust implementation through a selection of channels amongst which Blockchain Technology... Helbiz intends to distribute a fixed dollar amount per share dividend in-property, in the form of digital discount coupons, the details of which will be disclosed at a later date. These coupons will provide shareholders with exclusive discounts and benefits on a range of services, including micro mobility, ride-sharing, car rentals, food delivery, and early access and purchasing of retail vehicles like the Wheels One.The distribution of the digital dividend coupon will provide the company with a way to track the number of shares, allowing for a better understanding of the company's shareholder base.

09:19 EST Cosmos Holdings announces initial purchase order with Virax Biolabs - Cosmos Health (COSM) announces the first purchase order to market and distribute Virax Biolabs' (VRAX) ViraxClear branded COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to its previously signed distribution agreement dated September 2022, Cosmos Health will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.

09:14 EST AvidXchange launches AvidAnalytics, a business intelligence tool - AvidXchange announced AvidAnalytics, a premium Business Intelligence, BI, solution. AvidAnalytics offers buyer customers custom reporting methods to help improve spend management and drive stronger results and efficiency for the organization. "We launched AvidAnalytics because we know our buyer customers are managing an incredible amount of data through their invoice, purchase order and payment transactions, and standard reporting methods for spend management no longer cut it in today's digital-first era," said Serdar Dincaslan, Senior Vice President of Business Insights, Decision Science & Network Growth. "With AvidAnalytics, we're putting the power back into the buyer customers' hands to glean the insights they need from analyzing and reporting on their data to help strengthen the business overall."

09:12 EST GeoVax Labs expands Gedeptin clinical research - GeoVax Labs announced its clinical trial of Gedeptin for patients with recurrent head and neck cancers is now actively enrolling patients at three major research centers -- Stanford University, Emory University and Thomas Jefferson University. The Phase 1/2 trial is evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma, with tumor(s) accessible for injection and no curable treatment options. The protocol entails up to five treatment cycles, each consisting of three intra-tumoral injections of Gedeptin over two days followed by infusion of a prodrug, fludarabine phosphate, once a day for three days. A Phase 1 dose-ranging study, evaluating the safety of a single cycle of Gedeptin therapy, found the therapy to be well-tolerated, with evidence of a reduction in tumor size in patients with solid tumors. David Dodd, GeoVax President and CEO, commented, "The support of the FDA and collaborations with Stanford, Emory and Jefferson enable us to evaluate Gedeptin rapidly in 10 patients, with the potential to subsequently expand the trial to 25 patients. A successful outcome may lead to labeling discussions with the FDA and initiation of further Gedeptin investigations, including in combination with immune checkpoint inhibitors, for additional cancerous and non-cancerous tumor indications."

09:11 EST GSK, Cytel enter three-year agreement to expand Solara deployment - Cytel has entered into a three-year strategic agreement to expand GSK's deployment of clinical strategy platform Solara. This collaboration will provide critical input to future development of the Solara platform.The platform has the potential to enable GSK to efficiently align on trial goals, navigate trial uncertainties and produce pressure-tested clinical trial designs that minimize costs and accelerate speed to market.

09:09 EST Progyny down 6% after Spruce Point issues short report

09:08 EST Progyny shares down 6.5% premarket after Spruce Point issues negative report

09:07 EST Monarch Casino board initiates annual cash dividend of $1.20 per share - Commencing in the second quarter of 2023, the Board of Directors has approved the payment of an annual dividend in the amount of $1.20 per outstanding share of Common Stock, payable in quarterly amounts on the 15th day of the third month of each applicable calendar quarter to those stockholders of record on the 1st day of the third month of each quarter, to be reviewed quarterly by the Board. As such, for all of calendar year 2023, the Company expects to pay total cash dividends of $5.90 per share.

09:07 EST Roku and DoorDash team on DashPass, access to on-demand delivery from TVs - Roku (ROKU), and DoorDash (DASH) announced "a multi-year partnership to build a better TV experience and unlock new ways for consumers to access their favorite restaurants and more. The partnership includes: Complimentary DashPass: New and existing Roku account holders with a linked streaming or smart home device can get six months of complimentary DashPass .DashPass is DoorDash's membership program that offers members $0 delivery fees on eligible orders from thousands of restaurants, grocery, convenience, and retail stores nationwide. Shoppable Ad Offers: For the first year of the partnership, DoorDash will be the exclusive marketplace ad solution partner for DoorDash U.S. restaurants and grocers that buy interactive shoppable ads on Roku. This first-of-its-kind partnership empowers DoorDash merchants to place unique click-to-order offers within their Roku ads. For the first time, restaurant advertisers can partner with DoorDash and Roku to attribute, target, and measure TV streaming ads on Roku," noted the companies in a statement.

09:06 EST Monarch Casino board authorizes one-time cash dividend of $5.00 per share - Monarch Casino & Resort announced that its Board of Directors authorized a one-time cash dividend of $5.00 per share of its outstanding common stock. The one-time cash dividend is payable on March 15, 2023, to stockholders of record on March 1, 2023.

09:05 EST Digerati Technologies announces consolidation of operating subsidiaries - Digerati Technologies announced its plan to consolidate the Company's operating subsidiaries - T3 Communications, Inc., Nexogy, Inc., and NextLevel Internet, Inc. - into a single operating company under the new name of Verve Cloud, Inc. The new name, "Verve," describes the Company's passion and enthusiasm for delivering amazing experiences to its clients, partners, and employees. It is expected that the new name and brand will be fully implemented across the Company's products and services before the end of Digerati's fiscal year-end on July 31, 2023.

09:04 EST Elektrofi announces collaboration with Thermo Fisher - Elektrofi announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi's breakthrough ultra-high concentration subcutaneous products. Elektrofi's platform technology is designed to overcome the challenges of delivering biologic-based therapies by enabling patients to self-inject therapies at home rather than in a hospital setting. Based on strong preclinical validation and partner interest, the company expects to initiate multiple clinical trials in 2024. The collaboration with Thermo Fisher will facilitate the establishment of a platform cGMP line, scheduled to be operational in early 2024, that will support early clinical efforts across a wide variety of pipeline programs and enable rapid scale-up for late-stage and commercial development.

09:02 EST STMicroelectronics, Gridspertise enter new phase of collaboration - Gridspertise and STMicroelectronics announced in occasion of DistribuTECH 2023 that they have entered a new phase of their long-term collaboration on smart-meter technologies. The two companies' collaboration started in the early 2000's with one of Gridspertise's shareholders Enel; today more than 65 million Gridspertise smart meters deployed in Spain, Eastern Europe, and Latin America leverage the power-line communication technologies provided by ST. Moreover, ST's latest PLC system-on-chip has been integrated in Gridspertise smart meters for Italy to enable a near real-time cyber-secure communication channel for in-home devices; the so-called Chain 2 technology. Now, Gridspertise and ST are working together to extend Chain 2 to new metering solutions in the Gridspertise portfolio, making it suitable for the U.S. and other geographies. For end customers, Chain 2 technology improves awareness of the energy consumed and self-produced. It enables a multitude of new enhanced services that simplify their energy usage through home automation. Chain 2 technology encourages a more active role for all the players in the energy market, as well as the penetration of distributed renewable sources. For example, the technology allows to recommend to the end customer tailor-made behaviors based on real-time data production from its own generation system, like photovoltaic panels. It also enables the smart meter to collect real-time data on home appliances' consumption, that can be used, for example, to modulate the charging power of an EV charger according to the available capacity and other demands for power in the house. Furthermore, Gridspertise and ST are collaborating in multiple other areas, too. Beyond working on ANSI C communication standard for the U.S. market, the Companies are cooperating for the adoption of the latest DLMS1-certified standards into Gridspertise smart meters, to further enhance interoperability and interchangeability between devices and systems.

08:58 EST Secureworks announces retirement of CFO Paul Parrish - In a regulatory filing, Secureworks said that on February 3, CFO Paul Parrish notified the company of his decision to retire as CFO, in which position he served as the company's principal financial officer, effective as of May 5, 2023. The Board of Directors appointed Steve Fulton, formerly the company's Chief Product Officer, as the company's President, Customer Success, effective as of February 6, 2023. Wendy K. Thomas will remain in the role of CEO and relinquish the role of President.

08:56 EST Glimpse Group announces integration of conversational AI into VR platform - The Glimpse Group announced that its subsidiary company, Foretell Reality, has integrated conversational artificial intelligence into their virtual reality platform. This integration could revolutionize the way users interact and engage in virtual environments across multiple industries, including healthcare, education, training and marketing. The new conversational AI feature utilizes GPT-3 to enable virtual reality experiences to respond to natural language inputs from users. With this integration, users can communicate with virtual characters in a conversational manner on the Foretell VR platform, similar to real-life interactions. This is expected to provide a higher level of engagement in virtual environments, creating a more realistic and lifelike experience.

08:53 EST SKYX Platforms to acquire Belami in cash, stock transaction - SKYX Platforms announced that it signed a definitive acquisition agreement to acquire Belami, an established, profitable, strategic lighting and home decor e-commerce conglomerate with $86 million in revenues and 64 websites. The acquisition of the strategic e-commerce lighting and home decor conglomerate will serve SKYX as a marketing and growth platform that is expected to advance SKYX's business plan by years, provide several distribution channels including to retail customers, builders and professionals, as well as significantly enhance gross margins of SKYX's products. The acquisition payments will include a total of up to 5,223,991 shares of SKYX's common stock and $8 million in cash at close that has been fully funded by two major existing SKYX investors, with an additional $4 million deferred cash payment one year after close. The shares portion will include 2,018,692 restricted shares that will be delivered to Belami selling shareholders at close and an additional payment of up to 2,233,331 restricted shares that will be delivered to selling shareholders 1 year after close. Delivered shares are subject to lockouts and leak out provisions. In addition, SKYX has agreed to issue post-closing, 498,445 restricted stock units, 473,523 restricted shares, and options to purchase 300,000 shares of common stock to Belami's employees, consultants and management. The equity portion of the acquisition reflects a total of $16 million. SKYX has made a $1 million deposit to an escrow account at signing. SKYX has also agreed to assume Belami's loan agreement with PNC Bank, National Association, consisting of a $2.0 million available revolving line of credit and a term loan of approximately $2.5 million. In relation to this acquisition, on February 6, 2023, SKYX has closed a private placement offering of convertible notes, subject to acquisition closing, in the aggregate principal amount of $8.1 million, with 50% warrant coverage to a major SKYX investor that has invested over $6.0 million in this private placement. The private placement offering was led by two existing investors. The acquisition has been approved by SKYX's board of directors and is expected to close in the coming months, subject to closing conditions.

08:50 EST Ensysce Biosciences closes $3M registered direct offering - Ensysce Biosciences announced that it has closed its previously announced registered direct offering for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-market under NASDAQ rules. In addition, in a concurrent private placement, the Company issued warrants to purchase up to 3,571,431 shares of common stock. The warrants have an exercise price of $0.715 per share, are exercisable immediately following issuance and will have a term of five and one-half years from the issuance date. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering were approximately $3.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for general corporate purposes, which may include funding capital expenditures and working capital and repaying indebtedness.

08:48 EST PHI Group enters agreement with Thanh Nam Long Company - Philux Global Group announced today that Thanh Nam Long Co. has signed an agreement with Philux Global Group, Inc., the parent and sponsor of PHILUX Global Funds SCA, SICAV-RAIF, to join "PHILUX Infrastructure Fund," a Luxembourg-based infrastructure fund focusing on the development and implementation of selective infrastructure projects in Vietnam and other geographical areas that are compatible with the investment philosophy and strategy of the fund.

08:47 EST Orbit International appoints Marshall Sterman to board of directors - Orbit International announced that Marshall Sterman has joined its Board of Directors replacing Bernard Karcinell who passed away in November 2022. Mr. Sterman will be serving as Chairman of Orbit's Audit Committee and as a member of its Compensation and Nominating and Corporate Governance Committees . Mr. Sterman, who is a CPA, is currently President of HMS Advisors, LLC, a financial and strategic advisory services company. Previously, he was a partner at Mazars LLP's Manhattan office for 24 years.

08:44 EST SOBRsafe ships SOBRsure wearable bands for validation - SOBR Safe reached the final stage of product development for its alcohol monitoring wearable SOBRsure, shipping multiple pre-commercial units to industry experts for environmental validation. Thereafter, SOBRsafe intends to launch commercial production and sales efforts for the $875 million rehabilitation and $9.5 billion fleet & facility markets. Leveraging a proprietary app-based reporting interface, SOBRsure provides continuous alcohol monitoring and GPS tracking, with notifications to administrators upon alcohol detection or device removal. SOBRsafe previously received an initial purchase order for 1,150 white label bands for rehabilitation use, with the intent to accelerate telehealth intervention and improve recovery rates.

08:43 EST Twin Vee PowerCats partners with Suzuki to unveil 240 DC ECO boat - Twin Vee PowerCats released more details and images on its all-new 240 DC ECO. Twin Vee announced last month that its 240 DC GFX ECO would be one of the boats it plans to display at the Discover Boating Miami International Boat Show from February 15-19 at the Suzuki Oasis at the Venetian Marina & Yacht Club.

08:40 EST Greenlane prioritizes product innovation, family of brands, partnerships - Greenlane Holdings has prioritized its product innovation, family of brands, and strategic partnerships to accelerate company growth and success. Greenlane's family of brands offer an extensive product lineup aimed at various consumer demographics, with offerings from luxury glass pieces to artist collaborations to value-driven accessories. With 23 proprietary launches coming in 2023 from house brands including Eyce, DaVinci, Marley Natural, and K.Haring by Higher Standards, Greenlane will have a uniquely innovative year. Greenlane's newest house brand, Groove, has launched 12 new products providing the market with simple, functional, and reliable ancillary products at an affordable price point. The CARA by Groove, which launched in Q4, is a high quality concentrate pen at a value price, and continues to be highly successful. In addition to the launch of Groove, Greenlane plans to unveil additional new products at CHAMPS in Las Vegas starting February 8th. Recently, Greenlane expanded its global reach with strategic market distribution partners including in Latin America, Argentina, Canada, Puerto Rico, and Mexico. These partnerships enable Greenlane to reach consumers globally without the necessity of establishing operations in the locations and are key to Greenlane's strategy to continue to scale its brands worldwide. Additionally, Greenlane's relationships with partner brands including AUXO, CCELL, and Storz & Bickel offer consumers greater access to these innovative and desired products.

08:40 EST TC Biopharm doses final patient in phase 2B trial of OmnImmune in AML - TC Biopharm announced the official dosing of its final patient from the safety cohort for ACHIEVE, its phase 2B clinical trial of OmnImmune for treatment of Acute Myeloid Leukemia - AML -. TC BioPharm's trial involved administering TCB008, the company's novel drug to treat AML, to pathologically confirmed diagnosed patients afflicted with this type of cancer. Pending the final review of the Data Safety Monitoring Board, the company will move to open enrolment of the trial, and expect a positive formal review from the DSMB in February. The Phase 2B clinical trial is ongoing and is expected to enroll approximately 37 patients. TC BioPharm will report additional results as they become available.

08:39 EST MAG Silver closes $42.6M common share offering - MAG Silver announced that it has completed its previously announced bought deal public offering and has issued 2,905,000 common shares, including 170,000 Common Shares issued upon the partial exercise of the over-allotment option, at a price of $14.65 per Common Share for gross proceeds of $42,558,250. MAG intends to use the net proceeds of the Offering to fund exploration on Juanicipio and MAG's other projects including Deer Trail, certain sustaining capital requirements at the Juanicipio Project not included in the initial project capital estimates, and for working capital and general corporate purposes. The Offering was led by BMO Capital Markets and Raymond James Ltd. as the joint bookrunners, together with a syndicate of underwriters consisting of Canaccord Genuity Corp., H.C. Wainwright & Co., LLC, National Bank Financial Inc., Roth Canada Inc., TD Securities Inc. and Scotia Capital Inc.

08:38 EST Newtek Business Services raises $20M in sale of stock to Patriot Financial - NewtekOne has sold $20 million of the Company's 8% Convertible Series A Preferred Stock to Patriot Financial Partners IV, L.P. Barry Sloane, Chairman, President and Chief Executive Officer said, "Patriot Financial Partners is a sophisticated institutional investor that we believe can add value to our enterprise in a multitude of ways. In addition to having access to their deep bench of experience with bank executives with regulatory and banking backgrounds, we believe that introductions to institutions in which they have invested can be valuable to our portfolio of referral promotion agreement partnerships. We believe the Patriot investment, given the extensive analysis they performed, provides further validation for our transformation into a financial holding company."

08:37 EST Workday announces $250M expansion of its Workday Ventures fund - Workday announced a $250M expansion of its Workday Ventures fund. The additional $250M investment capital from Workday into Workday Ventures, the strategic capital arm of Workday Inc., builds on the company's solid performance and is the latest step in its journey to shape the future of work.

08:37 EST Color Star Technology partners with ARGS Productions to create Fans Circle - Color Star Technology subsidiary Color Metaverse has entered into a strategic cooperation framework agreement with ARGS Productions. Both parties plan to cooperate in the business of celebrity agency, celebrity performance and celebrity peripheral in the future. Color Star plans to develop a fan culture and create "Fans Circle", an entertainment service dedicated to everything associated with performance events, celebrities and their merchandise. Fans Circle operates in a closed loop, where one performance can generate business for a chain of related services. ARGS is a star agency in Japan representing Asian stars and groups such as SE7EN, OnlyOneOf, NIK, and EXID. Both parties plan to jointly develop the local fan culture in Japan, as well as a celebrity agency business in other regions. Color Star also plans to take advantage of its ColorWorld Metaverse platform to open up virtual celebrity meetings and offer exclusive rights to NFT stars.

08:36 EST Verizon achieves upload speeds surpassing 1 Gbps - Verizon engineers continue to drive the evolution of 5G Ultra Wideband technology achieving 1.26 Gbps in upload speed. With uploading data becoming increasingly important for video chats, uploading large files or live streaming video, this significant accomplishment is yet another milestone in Verizon's commitment to provide a genuinely differentiated service for customers.

08:36 EST FSD Pharma gets regulatory clearance for proposed trial of Lucid-MS - FSD Pharma announces the receipt of a No Objection Letter from Health Canada regarding the Company's proposed Phase 1 clinical trial of LUCID-21-302 , a novel drug candidate for the treatment of Multiple Sclerosis . The NOL provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada. The first-in-human clinical trial will evaluate the safety and tolerability of Lucid-MS, a neuroprotective compound with a unique mechanism of action for the treatment of MS. Lucid-MS is a patented New Chemical Entity NCE that has been the subject of more than 11 years of research and development. In preclinical models, Lucid-MS has been shown to prevent myelin degradation or demyelination, a known cause of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system. Preclinical evidence has demonstrated Lucid-MS to promote functional recovery in experimental animal models of MS (https://fsdpharma.com/our-science/). Based upon current evidence, Lucid-MS is non-immunomodulatory, an important distinction in the potential for developing new, safe options for treating MS. "There is an acute need today for effective, non-immunomodulatory, neuroprotective therapeutics, especially for the treatment of progressive stages of MS," said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma. "We are excited to receive the NOL regulatory clearance, and look forward to initiating the first clinical trial of this promising candidate as a critical steppingstone in our mission to develop novel therapeutics for the treatment of MS. We will continue to work with Health Canada and other regulators worldwide to complete clinical investigations as soon as we can."

08:34 EST CGI Inc. selected to transition State of Arizona HR management system - CGI announced its selection through a competitive process for a contract to replace the State of Arizona's human resource information system with a single solution anchored by CGI Advantage, a mobile-first platform that will power flexible, real-time applications for core HR, payroll, workforce management, talent management, strategic HR planning, and other essential HR functional areas across more than 100 agencies, boards and commissions.

08:33 EST Shell, S&W enter joint venture to develop novel plant genetics - Equilon Enterprises and S&W Seed Company announced the execution of an agreement to establish a joint venture for the purpose of developing novel plant genetics for oil seed cover crops as feedstocks for biofuel production. The JV company, named Vision Bioenergy Oilseeds LLC, will be jointly owned by Shell and S&W. The JV intends to develop Camelina and other oilseed species from which oil and meal can be extracted for future processing into animal feed, biofuels, and other bioproducts. S&W will contribute its expertise in seed research, technology, production, and processing to the JV, including its seed processing and research facilities in Nampa, Idaho.

08:30 EST Onconova announces additional clinical data on rigosertib - Onconova Therapeutics announced that the second of two evaluable participants in an investigator-initiated Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa achieved a complete response of all cancerous skin lesions following 4 treatment cycles and remains on oral rigosertib. Steven Fruchtman, M.D., President and Chief Executive Officer of Onconova, commented, "We are pleased to be building on this Phase 2 program's initial single-patient data with a second participant showing complete resolution of all cancerous skin lesions, with the most recent patient notably seeing this result after only four cycles of therapy. We look forward to reviewing our findings with the FDA to determine the most expeditious regulatory path for rigosertib in RDEB-associated SCC. In addition, these findings may have important implications beyond this orphan indication, as they and prior preclinical data demonstrate rigosertib's activity against the PLK1 protein. Although the company is focusing its resources mainly on the lead narazaciclib program, preclinical studies exploring rigosertib's activity in other PLK1-dependent tumors are underway and will hopefully open a broader regulatory path for rigosertib."

08:29 EST Indaptus activates Morristown Medical Center as trial site for INDP-D101 - Indaptus Therapeutics announces the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101. INDP-D101 is the Company's first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. Patient screening at the Morristown, NJ hospital is expected soon. "The continued expansion of trial sites will help to facilitate a potentially more rapid enrollment and get us to our initial data points, which, in turn will continue to facilitate the development of what we believe is a potentially important innovation in the treatment of solid tumors," said Jeffrey Meckler, Indaptus Therapeutics' CEO. "We look forward to collaborating closely with the investigators at Morristown Medical Center, and all of clinical trial sites, which we hope to be opening in succession in the coming weeks."

08:28 EST INFINT Acquisition announces contribution to trust account - INFINT Acquisition announced that, in connection with its previously announced extraordinary general meeting of shareholders of the Company to be held at 10:00 a.m. Eastern Time on February 14, 2023 for the purpose of considering and voting on, among other proposals, a proposal to extend the date by which the Company must consummate an initial business combination from February 23, 2023 to August 23, 2023 or such earlier date as may be determined by the Company's board of directors, in its sole discretion, additional contributions to the Company's trust account will be made following the approval and implementation of the Extension. If the requisite shareholder proposals are approved at the Extraordinary Meeting and the Extension is implemented, on the Current Termination Date, and the 23rd day of each subsequent calendar month until the Extension Date, the lesser of $290,000 and $0.06 per public share multiplied by the number of public shares outstanding on such applicable date. If a Contribution is not made by an applicable Contribution Date, the Company will liquidate and dissolve as soon as practicable after such date and in accordance with the Company's Amended and Restated Memorandum and Articles of Association, as amended. Any Contribution is conditioned on the approval of the requisite shareholder proposals at the Extraordinary Meeting and the implementation of the Extension. No Contribution will occur if such proposals are not approved or the Extension is not implemented. If the Company has consummated an initial business combination or announced its intention to commence winding up prior to any Contribution Date, any obligation to make Contributions will terminate. The Company expects that the proceeds held in the trust account will continue to be invested in United States government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended, as determined by the Company, or in an interest bearing demand deposit account, until the earlier of: the completion of the Company's initial business combination, and the liquidation of, and distribution of the proceeds from, the trust account.

08:26 EST Magnite announces next generation CTV, OTT monetization platform - Magnite announced Magnite Streaming, a singular supply-side platform that merges leading technology from the Magnite CTV and SpotX platforms. "Magnite Streaming empowers media owners to maximize the value of their assets holistically across live and VOD inventory, CTV and OTT environments, and addressable linear, while gaining insights to more efficiently and effectively drive their businesses," the company said. Magnite's CTV and OTT clients include AMC Networks, DISH Media, Disney Advertising, FOX Corporation, FuboTV, LG Ads Solutions, VIZIO, and Warner Bros. Discovery, among others. Sean Buckley, Chief Revenue Officer of Magnite, remarked "Consumers are embracing streaming as their preferred way of watching TV and increasingly adopting ad-supported services to gain access to more premium entertainment without straining their budgets. Media owners are eager to meet this demand and the challenge many face is how to integrate and manage high quality ad experiences across their diverse content portfolios. Magnite Streaming addresses these concerns by bringing together the leading technology and tools that a media owner needs at every stage of the advertising process in one unified platform."

08:24 EST Alpha & Omega falls after quarterly results, guidance miss estimates - Shares of Alpha & Omega are falling further in pre market trading on Tuesday, after reporting Q2 results and guidance that did not meet analyst consensus estimates on Monday evening. The company is currently down almost 12% to $31.95 per share in early trading. "AOS has been in business for over two decades and inventory corrections and market cycles are a natural and healthy part of our industry. Demand for more and better power management is being driven by what we call the 'electrification of everything'. We believe this tailwind is here to stay despite this temporary headwind, and we are in an excellent position to continue to win and thrive in this market.

08:23 EST BioSig CFO Steve Chaussy to retire, Steve Buhaly to succeed - BioSig Technologies announced the retirement of CFO Steve Chaussy following a distinguished career with the Company, and has named Steve Buhaly as his successor. Buhaly is a long-tenured finance and technology executive who joined Qorvo as CFO in 2007.Since 2018, Mr. Buhaly has served as an advisor to multiple early-stage and small businesses and currently consults for cancer treatment innovator UbiVac

08:20 EST Achieve Life Sciences doses last subject in Phase 2 ORCA-V1 trial - Achieve Life Sciences announced that the final subject of the Company's Phase 2 ORCA-V1 trial has completed treatment in the study. ORCA-V1 is evaluating the efficacy and safety of cytisinicline in adult users of nicotine e-cigarettes or vapes and is being supported in part through grant funding from the National Institute on Drug Abuse of the National Institutes of Health, The ORCA-V1 trial randomized 160 adult users of nicotine e-cigarettes across 5 clinical trial locations in the United States. Participants were randomized into two arms to either receive 3 mg of cytisinicline three times daily, or placebo, for a period of 12 weeks. Patients also received standardized behavioral support throughout the trial. The primary endpoint is continuous abstinence during the final 4 weeks of treatment. Dr. Nancy Rigotti, Professor of Medicine at Harvard Medical School and Director, Tobacco Research and Treatment Center, Massachusetts General Hospital is the primary investigator for the ORCA-V1 trial.

08:19 EST Lightbridge announces peer-reviewed paper on its fuel rods - Lightbridge Corporation announced that a recently published peer-reviewed technical paper on the disposition of weapons-grade plutonium revealed that a Lightbridge-designed fuel rod significantly outperforms traditional mixed-oxide fuel in consuming plutonium in a computer simulation, making the Lightbridge designed rods well suited for consuming excess weapons-grade plutonium. The paper's title is "Improved Disposition of Surplus Weapons-Grade Plutonium Using a Metallic Pu-Zr Fuel Design." The paper was co-authored by Braden Goddard, Ph.D., Assistant Professor, Department of Mechanical and Nuclear Engineering at Virginia Commonwealth University, and Aaron Totemeier, Ph.D., Senior Nuclear Fuel Consultant to Lightbridge, for Nuclear Technology, the leading international publication reporting new information on the practical application of nuclear science for peaceful uses. Seth Grae, President and CEO of Lightbridge, commented, "We are pleased with the acceptance and publication of this paper in this prestigious journal. The findings reported in this study were subject to rigorous review by top scholars, validating the plutonium disposition and proliferation resistance of this variant of Lightbridge Fuel rods. The findings will help to drive further awareness and support of Lightbridge Fuel within government and the private sector."

08:18 EST Principal Financial announces Vivek Agrawal to join as chief growth officer - Principal Financial Group announced Vivek Agrawal will join the company as chief growth officer effective March 7. Agrawal is currently Senior Partner at McKinsey & Company. During his tenure at McKinsey spanning more than two decades, Agrawal led McKinsey's practices in both the United States and Asia and has built considerable hands-on experience in the growth and turn-around of leading organizations in asset management, retirement, wealth management, and insurance sectors globally.

08:17 EST Immix Biopharma doses first two patients in Phase 1b/2a combination trial - Immix Biopharma announced dosing of the first 2 patients in its IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab Combination Phase 1b/2a Clinical Trial in patients with advanced solid tumors. Initial clinical data from this combination trial is anticipated to be released on a rolling basis beginning in 1H 2023. IMX-110 + Beigene/Novartis anti-PD-1 tislelizumab combination treatment is designed to enhance response to solid tumors by turning immunologically "cold" tumors "hot". In ImmixBio prior IMX-110 + anti-PD-1 preclinical experiments, a 50% improvement was produced by IMX-110 + anti-PD-1 in a genetic pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system, compared to a 4-drug combination of 2 chemotherapies and 2 immunotherapies in the same genetic pancreatic cancer mouse model.

08:16 EST Centogene regains compliance with Nasdaq listing requirements - Centogene announced that it has received a notification from the Nasdaq Stock Market Listing Qualifications Department informing the Company that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1). As a result, CENTOGENE is now compliant with all applicable Nasdaq listing standards, and Nasdaq considers this matter closed. CENTOGENE was previously notified by Nasdaq on December 12, 2022, that it was not in compliance with the minimum bid price rule, because its common stock failed to meet the closing bid price of US$1.00 or more for 30 consecutive business days. To regain compliance with the minimum bid price rule, the Company was required to maintain a minimum closing bid price of US$1.00 for at least 10 consecutive business days. This requirement was met on February 3, 2023.

08:13 EST Terex makes equity investment in Texas-based robotics company Apptronik - Terex has made an equity investment in Apptronik, an Austin-based company specializing in the development of versatile, mobile robotic systems whose goal is to bring forth the next generation of robots. Separate from the equity investment, the two companies have entered into a co-development agreement to work together to create potential robotic applications for Terex products. Apptronik's co-founders have worked on the NASA Valkyrie Robot for the DARPA Robotics Challenge. Other Apptronik projects include Astra, an upper-body humanoid robot and, most recently, Apollo, a NASA-backed versatile humanoid designed to scale and apply to numerous applications.

08:09 EST Orchestra BioMed appoints Avi Fischer as SVP, medical affairs, innovation - Orchestra BioMed announced the addition of several highly accomplished industry veterans to its senior leadership team. Avi Fischer, M.D., joins as Senior Vice President, Medical Affairs and Innovation, and J.C. Simeon assumes the role of SVP, Quality. George Papandreou, Ph.D., has been promoted to General Manager and SVP of Focal Therapies, previously SVP, Quality and Kunal Faldu has been promoted to Vice President of Pharmaceutical Development, previously Senior Director, Formulation Development. Most recently, Fischer served as Chief Executive Officer of ElectroPhysiology Frontiers, S.p.A., a privately held medtech company developing a single-shot ablation system to treat atrial fibrillation. Simeon previously worked for Amring Pharmaceuticals as Head of Quality Assurance and Regulatory Affairs and was also Executive Director of Quality at Actinium Pharmaceuticals.

08:08 EST Dave & Buster's: Dave & Buster's World opens virtual doors on Roblox - Dave & Buster's (PLAY) announced its entry into the metaverse as Dave & Buster's World opens its virtual doors on Roblox (RBLX). Dave and Buster's World on Roblox is an interactive and immersive digital experience that reflects the energy and excitement of the actual Dave & Buster's. Each game is designed for multi-user experiences enabling friends to play together and connect in some of their favorite games in a bold new way.

08:06 EST Marpai hires Gonen Antebi as COO - Marpai has hired Gonen Antebi as its Chief Operating Officer. Most recently, Antebi has served as the Chief Executive Officer of Nuvem Health, where he created the teams, technology and processes that drove a small start-up into an industry leader in just seven years. Prior to Nuvem, Antebi gained vast experience in healthcare data and third-party administration serving as Chief Operating Officer at ArroHealth and as Chief Executive Officer of MedSave USA, Inc.

08:05 EST Royal Caribbean sees FY23 CapEx $4.1B - Capital expenditures for the full-year 2023 are expected to be approximately $4.1B, based on current foreign exchange rates and are predominantly related to the company's new ship order book. The company expects to take delivery of three new ships in 2023 including Icon of the Seas, Celebrity Ascent and Silver Nova. All ship orders have committed financing in place. Non-new ship related capital expenditures are expected to be $0.5B. Capacity changes for 2023 are expected to be 14% compared to 2019. Capacity changes for 2024, 2025 and 2026 are expected to be 10%, 5%, and 6%, respectively. These figures do not include potential ship sales or additions that the company may elect in the future.

08:04 EST Royal Caribbean 'very encouraged about the demand environment for 2023' - The company is very encouraged about the demand environment for 2023. Booking volumes in the fourth quarter were significantly higher than the corresponding period in 2019, culminating in record booking weeks for the Group for both Black Friday and Cyber Monday. Momentum continues into early 2023 and the company is experiencing a record-breaking WAVE season. Overall, the seven biggest booking weeks in the company's history have occurred since the middle of November 2022, including the first five weeks of WAVE. The booking window has continued to move back to normal, providing further confidence in forward looking business, as guests plan for the future. Consumer spending onboard and pre-cruise purchases continue to exceed prior years driven by greater participation at higher prices, indicating quality and healthy future demand. The cumulative booked position remains well within historical ranges at record rates and has improved significantly since November. North America sailings, many of which visit Perfect Day at CocoCay, are leading the way and are booked in line with record 2019 levels for the full year and ahead for the second quarter through the fourth quarter. Bookings for European itineraries have been accelerating during WAVE and are now higher than 2019.

08:02 EST PharmaTher submits FDA meeting package for KETARX pump system - PharmaTher Holdings submitted its Type B meeting package with the U.S. Food and Drug Administration to discuss the remaining requirements for the KETARX On-Body Pump System and submission of a New Drug Application under the 505(b)(2) pathway. PharmaTher aims to leverage its own CMC information, clinical data and available non-clinical and clinical data to submit an NDA by the end of 2023. The meeting date with the FDA is set for March 23, 2023. PharmaTher aims to obtain FDA approval for the KETARX On-Body Pump System for the maintenance of anesthesia and as a supplement to other anesthetic agents in alignment with ketamine's FDA-approved label. In addition, the use of the KETARX On-Body Pump System for sedation during short-term diagnostic and surgical procedures is also being explored to extend the label for specific areas of application or types of procedures where the subcutaneous route of administration would be viable. This approach supports and potentially improves the administration of ketamine in both hospital and clinical settings. The Company believes that subcutaneous infusion of racemic ketamine via the KETARX On-Body Pump System has several advantages over commonly used intravenous administration, including decreased requirement for skilled personnel for its administration, reduction in pain and irritation associated with administration, and a reduced risk of systemic infection and other complications seen with IV administration. Subsequently, should the KETARX On-Body Pump System obtain FDA approval, it will allow the Company to leverage its regulatory package and clinical data to expand to mental health, neurological and pain disorders. This is further supported by the KETARX On-Body Pump System's capability to provide either anesthetic or subanesthetic dosing over a defined time period.

07:58 EST Nikola's Tre electric vehicle eligible for California incentive program - Nikola has received approval from the California Air Resources Board - CARB - for Nikola's Tre hydrogen fuel cell electric vehicle - FCEV - to be eligible for CARB's Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project - HVIP - program. This approval will now enable customers of Nikola's Tre FCEV to access a point-of-sale incentive starting at $240K and ranging up to $288K per truck, in 2023. Customers will also be eligible for a $40K clean commercial vehicle tax credit from the federal government due to the passage of the Inflation Reduction Act. California's HVIP is an incentive program intended to advance commercialization and to help reduce the total cost of ownership of hybrid and zero-emission commercial vehicles in the state of California.

07:47 EST Ebix reports 'record volumes' on AnnuityNet4 in 2022 - Ebix announced that it closed 2022 with record volumes on its Annuity Exchange Platform called AnnuityNet4. In the year 2022, Ebix recorded some of its highest numbers ever in many areas: Total annuity premiums processed through the platform reached $98 billion, the highest ever since inception in 1997. This represents a 46 percent gain as compared to 2021. Total transactions exceeded 580,000. This represents 36% year-over-year growth in 2022. Q4 2022 was the highest ever quarter on record in terms of transaction counts, with November 2022 being the highest ever month on record. The number of participants on the exchange now stands at 57 carrier manufacturers and over 120 distributors, including banks and clearing houses. Total number of products supported on the platform crossed 2,400.

07:45 EST Avicanna expands partnership with Viola Brands - Avicanna entered into a new sub-license agreement with VB Brands California and Player Holdings LLC to exclusively commercialize its Viola-branded products in the United Kingdom territory where the company has entered into a sub-licensing agreement with Vertical Pharma Resources Limited T/A IPS Pharma for the manufacturing and distribution of the products. Expanding from the initial partnership in Canada where Avicanna successfully launched 9 SKUs of Viola-branded products across medical and adult use channels, the two companies have opened a new territory with their expansion into the UK. Starting late Q1 2023, Viola's purpose-driven vision, rooted in social equity and social justice will be available to patients in the UK through the exclusive licensing agreement. To facilitate the expansion, Avicanna has entered a sub-licensing agreement with IPS Pharma, a local pharmaceutical distribution company with more than 20 years of experience with unlicensed medicines to support the launch of the product offerings. The initial products will be manufactured in the UK under GMP guidelines and distributed through IPS' Pharma's existing network of pharmacies via medical prescription under the Special Access Program. The initial products offered in the UK will include proprietary formulations of vaporizers in THC-dominant and balanced CBD:THC ratios and will be supported by medical education and training.

07:39 EST Agco sees FY23 EPS $13.50, consensus $13.55 - Sees FY23 revenue $14B, consensus $13.76B. The company said, "AGCO's net sales for 2023 are expected to be approximately $14.0 billion, reflecting improved sales volumes and pricing partially offset by negative foreign currency translation. Gross and operating margins are projected to improve from 2022 levels, reflecting the impact of higher sales and production volumes as well as pricing to offset cost inflation. These improvements are expected to fund increases in engineering and other technology investments to support AGCO's precision agriculture and digital initiatives. Based on these assumptions, 2023 earnings per share are targeted at approximately $13.50."

07:38 EST NFI Group announces Southern Nevada's RTC ordered 24 high-capacity buses - NFI Group announced that the Regional Transportation Commission of Southern Nevada, RTC, has exercised options for 24 Xcelsior compressed natural gas, CNG, 60-foot, heavy-duty transit buses, converted from its subsidiary New Flyer of America's backlog in Q4 2022. RTC is a regional entity overseeing public transportation, traffic management, and roadway design and construction funding for Southern Nevada. RTC's public transit system delivers more than 64 million annual passenger rides in the greater Las Vegas Valley. The options are part of a five-year contract with RTC announced in 2021 for up to 130 Xcelsior CNG sixty-foot buses, supported by Federal Transit Administration, FTA, funds. "New Flyer is a leader in low- and no-emission mobility, with more than 13,000 CNG buses on the roads across North America. For over 30 years, RTC has partnered with New Flyer to deliver more than 820 buses, nearly half of which were CNG propulsion," said Chris Stoddart, President, North American Bus and Coach, NFI. "Each low-emission, quiet Xcelsior CNG bus emits 90% less nitrogen oxide compared to traditional diesel engines. Together with RTC, we are creating a more livable, connected, and healthy Las Vegas Valley community."

07:37 EST Parsons announce broadband internet effort - Parsons Corporation is leveraging its full spectrum of communications design, program and project management, radio frequency planning, and engineering expertise to help deliver broadband access across the United States. As part of this effort, the company was recently awarded a multi-million-dollar contract to design hundreds of miles of fiber optic installations along freeways for underserved communities.

07:34 EST Syneos Health, Haystack Health partner to accelerate trials with AI - Syneos Health (SYNH) announced a strategic partnership with Haystack Health, a Roivant Health (ROIV) portfolio company developing advanced Artificial Intelligence and Natural Language Processing solutions, to improve the identification and enrollment of patients for clinical trials. The combined capabilities of Syneos Health and Haystack Health will more effectively and efficiently identify and match clinical trial opportunities for patients. For sponsors and sites, this partnership will deliver valuable research tools and workflow efficiencies that result in improved timelines and increased patient recruitment. Initially, these new data solutions will only be available for Syneos Health sites in the US, with a focus on oncology and immunology. "The challenges of enrolling patients in clinical trials are well documented. Protocol complexity and specificity in precision medicine have made patient recruitment even more difficult. Haystack Health offers an advanced solution leveraging AI to match patients to trials while preserving privacy," said Baba Shetty, President, Technology & Data Solutions, Syneos Health. "We're thrilled to be working closely alongside the Haystack Health team to innovate in this critical area for patients, sponsors and science."

07:32 EST Hertz reports Q4 operating cash flow $277M - Operating cash flow was $277M for the quarter. Fleet capex of $312M was a source of cash in the fourth quarter, driven by fleet rejuvenation and seasonal de-fleeting. As a result, adjusted free cash flow was $424M, reflecting a 137% conversion from Adjusted Corporate EBITDA. The company acquired 19M shares, or 6% of its common stock, during the quarter.

07:22 EST Elite Pharmaceuticals reports results from bioequivalence study - Elite Pharmaceuticals reported results from pivotal fasted bioequivalence studies for an undisclosed generic drug product in a class of medications called antimetabolites . IQVIA reported annual sales for the twelve months ending December 2022 of $42 million for the generic market for this product. The studies were open label, single-dose crossover comparative bioavailability studies in volunteers of male and female patients who were already on established drug regimens under fasting conditions. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.

07:21 EST Lizhi drives business growth with AI-powered voice technology - LIZHI has recently made new headway with its proprietary AI-powered voice technology, which has been integrated into LIZHI's self-developed real-time communication, RTC, audio and video streaming solution DOREME with LIZHI's in-product interactive social functions. Incorporating AI and voice technology into the Company's platforms also supports the continued innovation of LIZHI's audio products and improvements to the user experience. At the same time, LIZHI will continue to conduct in-depth research on AI-generated content and language processing technologies in order to explore the application and expansion of these groundbreaking technologies in LIZHI products.

07:20 EST Enthusiast Gaming's EV.IO wins multiple game of the year awards - Enthusiast Gaming Holdings announces that its browser-based, first-person shooter game, EV.IO, "continues to attract industry accolades as a pre-eminent web3 gaming offering," including recently winning FPS Game of the Year and Esports Game of the Year at the Web3 Gam3rs Choice Awards earlier this week, following wins in the categories of best esports title and best multiplayer title at the Polkastarter GAM3 Awards in December. "We are thrilled to continue to be recognized amongst the top web3 games by our industry peers," said Bill Karamouzis, President of Enthusiast Gaming. "Our goal with EV.IO has always been to reach web3 gamers in an authentic way with first-class gameplay, while also providing brands a unique way to reach new audiences. Our upcoming roadmap includes adding AI to continue amplifying the gameplay experience."

07:18 EST Arch scientist awarded CIHR grant to study role of DPEP-1 in CKD - Arch Biopartners announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources Project Grant worth $1,109,250 to further study the role of dipeptidase-1 in renal inflammation and chronic kidney disease. The CIHR grant entitled "A Multifaceted Function for Dipeptidase-1 in Kidney Injury" was awarded to a research team at the University of Calgary led Dr. Daniel Muruve. Dr. Muruve is also the Chief Science Officer of Arch. The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD.

07:15 EST First Wave BioPharma regains compliance with Nasdaq requirement - First Wave BioPharma announced that on February 6, 2023, the Company received formal notice from the Nasdaq Hearing Panel indicating that First Wave BioPharma has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and advised that the Panel's oversight process of the Company is now closed. The Panel previously notified the Company on December 20, 2022, that the Company had regained compliance with the minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) based on the Company's representation that following the closing of its private placement offering for gross proceeds of approximately $2.5M on November 22, 2022, the Company believed it had stockholders' equity in excess of the $2.5M required under the Minimum Stockholders' Equity Requirement.

07:14 EST Genenta, AGC Biologics enter development, manufacturing service agreement - Genenta Science has entered into a development and manufacturing service agreement, MSA, with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing and quality/regulatory services, supported by scientists with 30 years of knowledge and experience. "The expansion of our existing relationship with AGC Biologics underscores the progress of our platform's clinical development. Based on results from Phase 1 of the ongoing Phase 1/2 clinical trial, we are scaling up the manufacturing process to be ready for Phase 2 of the trial," said Pierluigi Paracchi, Chief Executive Officer of Genenta. "This investment in manufacturing represents a significant step forward based on our expectation that our treatment has the potential to impact the tumor micro-environment and break immune tolerance in solid tumors." Genenta had an existing manufacturing services agreement with Molecular Medicine S.p.A.'s facility in Milan, which was subsequently acquired by AGC Biologics in 2020. The Milan site has been manufacturing lentiviral vectors and drug product for Genenta's ongoing programs since 2016, starting with the initial process development steps. The services provided under this existing agreement are in addition to the services that will be provided under the AGC Biologics MSA.

07:13 EST Graphic Packaging on track to meet Vision 2025 financial goals - Goals include adjusted EPS of $3.25+, sales of $10B-$12B, adjusted EBITDA $2B-$2.4B.

07:12 EST PGT Innovations announces $250M share repurchase program - PGT Innovations announced that its board of directors has approved a share repurchase program with authorization to purchase up to $250M of its common stock through February 3, 2026.

07:12 EST Medicenna Therapeutics announces upcoming milestones - Expected Upcoming Milestones: Initial PK/PD data from the ABILITY study's fifth dose escalation cohort and updated anti-tumor activity data from the first four dose escalation cohorts are expected in calendar Q1 2023. Early anti-tumor activity data from the ABILITY study's sixth dose escalation cohort and single agent expansion phase (Phase 2) are expected in calendar Q3 2023. Early anti-tumor activity data from the ABILITY study's combination arm are expected in calendar Q4 2023.

07:10 EST Rocket Pharmaceuticals announces RMAT designation for RP-A501 from FDA - Rocket Pharmaceuticals announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to RP-A501, the company's investigational adeno-associated virus, or AAV-based gene therapy for the treatment of Danon Disease, a devastating and fatal genetic cardiac disease for which there are no disease-altering therapies available. RMAT designation was granted based on positive safety and efficacy data from the Phase 1 RP-A501 clinical trial and will provide the benefits of added intensive FDA guidance and expedited review through the program's development.

07:08 EST Xortx Therapeutics provides update on 2023 planned milestones - XORTX Therapeutics provides a summary of Company's progress in 2022 and milestones planned for 2023. Dr. Allen Davidoff stated, "2022 marked a year of substantial technological and clinical progress and established the foundation for the Company's 2023 goals. The advancements and accomplishments made could not have happened without the efforts of our Board of Directors, employees, consultants, vendors, and shareholders. During 2023 we believe the goals set for 2023 will advance our technology closer to marketing approval and transform XORTX into a high value company." Goals for 2023: In 2023, XORTX will be focused on advancing XORLOTM as part of the XRx-008 for ADPKD into a Phase 3 registration clinical trial, the submission of an Orphan Drug Designation, initiation of special protocol assessment discussions with the FDA and initiation of commercialization activities for XORLOTM as well as advancing research in other kidney disease applications. To achieve these objectives, XORTX's action plan includes: Initiate XRX-OXY-301 Registration supporting "Accelerated Approval" of XORLOTM for individuals with ADPKD: This study will provide data to support a future "Accelerated Approval" new drug application submissions to the FDA and EMA. This study is planned to start in the second half of 2023 and will enroll individuals with stage 2, 3 or 4 ADPKD accompanied by chronically high uric acid. Complete Orphan Drug Designation. XORTX's ODD application was filed in January 2023, with anticipated feedback from the FDA ODD office within 90 days and ODD status during the first half 2023. Prepare and Communicate with the FDA and EMA regarding the XRX-OXY-302 Registration trial in ADPKD: XRX-OXY-302 is a Phase 3, Multi-Center Study to Evaluate the Efficacy and Safety of a Novel Oxypurinol Formulation in Patients with Progressing Stage 2-4 ADPKD and Coexistent Hyperuricemia. with progressing stage 2, 3, or 4 kidney disease. This study is planned to start in the second half of 2024, subject to Special Protocol Assessment negotiations with the FDA. Ongoing CMC Work: In parallel with the XRX-OXY-301 and XRX-OXY-302 studies, XORTX will be focus scale-up, validation and stability testing of clinical drug product supplies of XORLOTM under the Company's granted IND, as well as future clinical and commercial supplies. All development will be performed according to current GMP methodology. This work will be ongoing throughout 2022 and 2023. Activities Related to Potential Commercial Launch: In preparation for a possible "Accelerated Approval" NDA filing in 2025 in the U.S. for XORLOTM for XRx-008, XORTX will conduct commercialization studies, including nephrologist, patient, payer interviews, to support in-depth analysis of pricing and/or reimbursement, as well as product brand name selection and filings, and plans for launch. This work will be ongoing from 2023 to 2025. Activities Related to European Registration: XORTX will continue to work with and seek out guidance from the EMA to facilitate the path to approval of XORLOTM in the European Union, including required clinical studies and reimbursement conditions. This work will be ongoing from 2023 through 2026, and will include future drug orphan status.

07:01 EST OneMain expects receivables to reach $400M-$500M at year-end 2023 - Cards expected to drive $100M+ of annual capital generation by 2025, OneMain said in slides being presented on the Q4 earnings conference call.

06:48 EST Hut 8 Mining, US Bitcoin Corp to combine in all-stock merger of equals - Hut 8 Mining and U.S. Data Mining Group, dba US Bitcoin Corp, or USBTC, builder and strategic operator of four Bitcoin mining centers across the United States, announced that each of their boards of directors have unanimously approved a definitive business combination agreement under which the companies will combine in an all-stock merger of equals. The combined company will be named Hut 8 Corp. and will be a U.S.-domiciled entity. The transaction is expected to establish New Hut as a large scale, publicly traded Bitcoin miner focused on economical mining, highly diversified revenue streams, and best practices in ESG. Pursuant to the business combination agreement, shareholders of Hut 8 will receive, for each Hut 8 share, 0.2 of a share of New Hut common stock, which will effectively result in a consolidation of the Hut 8 shares on a 5 to 1 basis. Stockholders of USBTC will receive, for each share of USBTC capital stock, 0.6716 of a share of New Hut common stock. Based on the five-day VWAP for the Hut 8 shares on the Nasdaq as of the last trading day prior to the date of this announcement, the aggregate Consideration implies a combined market capitalization of approximately $990M. Upon consummation of the transaction, existing Hut 8 shareholders and USBTC stockholders will each collectively own, on a fully-diluted in the money basis, approximately 50% each of the stock of the combined company. Following completion of the transaction, Hut 8 and USBTC will each become wholly-owned subsidiaries of New Hut. Under the terms of the business combination agreement, the transaction will be effected by way of a court-approved plan of arrangement involving Hut 8 under the Business Corporations Act and a statutory merger involving USBTC under the laws of the State of Nevada. The arrangement will require the approval of at least 66 2/3% of the votes cast by the shareholders of Hut 8 voting at a special meeting of Hut 8's shareholders. The merger is also subject to the approval of USBTC stockholders. Completion of the transaction is subject to regulatory and court approvals and other customary closing conditions. Regulatory approvals expected to be required include receipt of approval under the Competition Act and under the United States Hart-Scott-Rodino Antitrust Improvements Act. In addition, the arrangement will require the approval of the Supreme Court of British Columbia, New Hut's common stock will require approval for listing on the Toronto Stock Exchange and The Nasdaq Capital Market. The business combination agreement includes non-solicitation provisions for both Hut 8 and USBTC, with Hut 8 maintaining a fiduciary out to accept a superior proposal, subject to USBTC's right to match and other customary exceptions. Hut 8 is required to pay USBTC a termination fee of $10M in certain circumstances. Officers and Directors of Hut 8 have entered into support and voting agreements with USBTC, agreeing to vote their Hut 8 shares in favor of the arrangement. Officers, directors, and certain stockholders of USBTC have entered into a stockholder support agreement with Hut 8, agreeing to vote their USBTC stock in favor of the merger. It is anticipated that the meeting and the receipt of the written consent of USBTC stockholders will occur in the second quarter of 2023. Closing is expected to occur thereafter, subject to satisfaction of the closing conditions under the business combination agreement. Pursuant to the business combination agreement, Hut 8 has also agreed to provide USBTC with secured bridge financing during the interim period, with the expected amount of such financing ranging from $6M-$6.5M, subject to the completion of definitive loan documentation. Following completion of the transaction, the shares of New Hut will trade on the Toronto Stock Exchange and the Nasdaq Stock Market, subject to approval or acceptance of each exchange in respect of the transaction. Each of Hut 8's and USBTC's respective board of directors have unanimously approved the business combination agreement and the transaction. Stifel GMP provided a fairness opinion to the board of directors of Hut 8 stating that, as of the date of such opinion, and based upon the scope of review and subject to the assumptions, limitations and qualifications stated in such opinion, the USBTC exchange ratio provided for in the business combination agreement is fair, from a financial point of view, to Hut 8. The board of directors of Hut 8 also received a second, independent fairness opinion from the Duff & Phelps Opinions Practice of Kroll, LLC stating that, as of the date of such opinion and based upon the scope of review and subject to the assumptions, limitations and qualifications stated in such opinion, the USBTC exchange ratio provided for in the business combination agreement is fair, from a financial point of view, to Hut 8. Following the closing of the transaction, the combined company will be domiciled in the United States and will be led by a proven leadership team that builds on the strengths and capabilities of both companies. The senior executive team and board of directors of Hut 8 will be enhanced by the addition of new members of USBTC who have significant knowledge and experience to support the combined operations. The Board of Directors of New Hut will consist of 10 directors, comprised of 5 directors from Hut 8 and 5 directors from USBTC.

06:35 EST Lithium Americas gets favorable ruling on record of decision for Thacker Pass - Lithium Americas received a favorable ruling from the U.S. District Court, District of Nevada on February 6 for the appeal filed against the Bureau of Land Management for the issuance of the Record of Decision relating to the company's 100%-owned Thacker Pass project located in Humboldt Country, Nevada. The Federal Court has declined to vacate the ROD for the mining Plan of Operations. The favorable ruling by the Federal Court confirms the permitting process for Thacker Pass was conducted thoroughly and responsibly, and results in there being no impediment to commencing construction. The Federal Court ordered the BLM to consider one issue under the mining law relating to the area designated for waste storage and tailings and did not impose any restrictions expected to impact the construction timeline. "We are pleased that the Federal Court has recognized the BLM's decision to issue the Federal Permit, reflecting our considerable efforts to ensure Thacker Pass is developed responsibly and for the benefit of all stakeholders," said Jonathan Evans, President and CEO. "The favorable ruling leaves in place the final regulatory approval needed in moving Thacker Pass into construction."

06:34 EST Premier implements cost reduction plan, reduces workforce by nearly 4% - Premier implemented a cost-savings plan in Q3 to better align its cost structure with its long-term strategy and position the business for the current macroeconomic environment. As part of this plan, the company is lowering certain expenses, including non-labor costs; eliminating more than 70 open positions; and reducing its workforce by nearly 4%, or approximately 100 positions. These actions are expected to produce pre-tax cost savings in the ranges of $18M-$20M in FY23 and $35M-$40M on an annual run-rate basis. The company expects the workforce reduction to result in pre-tax cash restructuring charges of approximately $8M which will be expensed in Q3 of FY23.

06:30 EST Nintendo reports 9M hardware units sold 14.91M, down 21.3% y-o-y - The company said, "Looking at the Nintendo Switch business during the nine months ended December 31, 2022, Pokemon Scarlet and Pokemon Violet got off to a strong start, recording total sales of 20.61 million units during the period. Other new titles released during this fiscal year also performed well, with Splatoon 3 selling 10.13 million units, and Nintendo Switch Sports selling 8.61 million units. In addition, among the titles released through the end of the previous fiscal year, Mario Kart 8 Deluxe sold 6.66 million units and Kirby and the Forgotten Land sold 3.47 million units. As a result of these factors, the total number of million-seller titles during this period was 27, including titles from other software publishers. As for hardware, units sold declined 21.3% year-on-year to 14.91 million units, mainly due to a shortage of semiconductors and other component supplies that impacted production until around late summer. Total software sales declined 4.0% year-on-year to 172.11 million units, affected to some extent by the decline in hardware sales. Turning to the digital business for our dedicated video game platform, sales of downloadable versions of packaged software for Nintendo Switch performed well, and revenue related to Nintendo Switch Online increased, helping to push digital sales to 310.0 billion yen, up 21.5% year-on-year. For the mobile and IP-related business, royalty income was stable but income from smart-device content declined, with the result that overall sales declined 2.3% year-on-year to 38.9 billion yen."

06:07 EST Oaktree Specialty Lending increases dividend 2% to 55c per share - Oaktree Specialty Lending declared a quarterly distribution of 55c per share, an increase of 2%, or 1c per share, from the prior quarter and the eleventh consecutive quarterly distribution increase. The distribution is payable in cash on March 31, 2023 to stockholders of record on March 15, 2023.

06:01 EST Gartner raises share repurchase authorization by $400M

05:53 EST Renault, Nissan announce details of reshaped alliance - Following approval by the Boards of Directors of Renault Group (RNSDF) and Nissan Motor (NSANY), Renault-Nissan-Mitsubishi Alliance announced new initiatives to take their partnership to the next level. three-dimension program to maximize value creation for all Alliance stakeholders will include: High-value creation operational projects in Latin America, India and Europe; Enhanced strategic agility with new initiatives that partners can join; A rebalanced Renault Group-Nissan cross-shareholding and reinforced Alliance governance. Renault Group and Nissan have entered into a binding framework agreement regarding the above mentioned transactions, with a view of reaching definitive agreements by the end of the first quarter of 2023. The transactions contemplated in these definitive agreements would be subject to a limited number of conditions precedent, including regulatory approvals, and completion is expected to occur in the fourth quarter of 2023. Nissan's intention is to invest up to 15% in Ampere, Renault Group's EV & Software entity in Europe, with the aim to become a strategic investor. Through this intended investment in Ampere Nissan would enhance and accelerate new business opportunities for Nissan in Europe. Mitsubishi Motors would consider investing in Ampere. Nissan and Mitsubishi Motors would become customers of Renault Group's Horse project, an initiative to achieve further scale and market coverage for its low-emission internal combustion engine & hybrid powertrain technologies. Nissan and Renault Group would retain a 15% cross-shareholding, with a lock-up obligation, as well as a standstill obligation. Renault Group would transfer 28.4% of Nissan shares into a French trust. Reference Link

05:10 EST Synaptics announces new chief people officer, chief product officer - Synaptics (SYNA) announced that it added Lori Stahl as chief people officer and Vikram Gupta as SVP and GM of IoT Processors and chief product officer. As chief people officer, Stahl will be responsible for executing Synaptics' human resource, or HR, strategy and employee programs worldwide. Stahl comes with 25 years of experience in almost all human resources disciplines across the technology, insurance, and renewable energy industries. Prior to Synaptics, she was chief people officer at Vocera Communications. In his role as SVP and GM of IoT Processors and chief product officer, Gupta will lead Synaptics' embedded and edge processing division, or EEPD. Gupta joins Synaptics from Infineon Technologies, where he served as SVP and GM of IoT compute and wireless business lines.